By hindustantimes.com | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON AUG 03, 2021 10:56 AM IST
Glenmark Life Sciences IPO opened for three days last month and was subscribed nearly 45 times. Its price range was at ₹ ₹695-720 per share and the lot size was 20. Ahead of its IPO, Glenmark Life Sciences raised ₹454 crore from anchor investors.
By hindustantimes.com | Written by Meenakshi Ray, New Delhi
PUBLISHED ON JUL 26, 2021 10:49 AM IST
Glenmark Life Sciences IPO will have a fresh issue of equity shares worth up to ₹1,060 crore and an offer for sale (OFS) of up to 63 lakh equity shares by Glenmark Pharmaceuticals.
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
Bengaluru | By Reuters| Posted by Susmita Pakrasi
UPDATED ON OCT 09, 2020 08:44 PM IST
Favipiravir is made under the brand name Avigan by Japan’s Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014, while umifenovir is licensed as a treatment for some types of flu infections in Russia and China.
UPDATED ON JUL 13, 2020 09:28 PM IST
The Drugs Controller General of India (DCGI) granted it approval for Covid-19 treatment under emergency use authorisation, which means since there is limited data available on the medicine’s performance on Covid-19 positive cases, doctors prescribing it would have to document the written consent of a patient.
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Sohini Sarkar
UPDATED ON JUN 20, 2020 10:44 PM IST
Bringing some relief for Covid-19 patients, even as the country reported an all-time high of 14,516 new coronavirus cases on Saturday, the drug will soon be available in hospitals and stores in a pack of 34 oral tables at moderately affordable prices.
Bengaluru | By Press Trust of India
PUBLISHED ON JUN 19, 2020 08:25 PM IST
The company has received the manufacturing and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the treatment of mild to moderate COVID-19 patients, it said.
UPDATED ON MAY 26, 2020 05:36 PM IST
Favipiravir is an oral antiviral drug approved in Japan since 2014 for treating novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licenced for the treatment and prophylaxis of influenza A and B infections in Russia and China.
Mumbai | By Asian News International | Posted by Kanishka Sarkar
UPDATED ON MAY 26, 2020 11:50 AM IST
A total of 158 hospitalised patients of moderate Covid-19 infection will be enrolled in the combination study and randomised in two groups.
UPDATED ON MAY 13, 2020 04:58 AM IST
Glenmark Pharmaceuticals Limited will be looking at recruiting patients from hospitals in the red zones of states such as Gujarat, Maharashtra and Delhi where the Covid-19 case load is high.
PUBLISHED ON MAY 01, 2020 03:49 AM IST
Favipiravir, sold under the brand name Avigan of Fujifilm Toyama Chemical Co. Ltd, Japan, a subsidiary of Fujifilm Corporation, is an antiviral medication used to treat influenza in Japan.
Hindustan Times, Jaipur | By HT Correspondent, Jaipur
UPDATED ON APR 24, 2018 10:34 PM IST
Drug controller-II, Jaipur, has said that a second DCGI team will probe the matter further.